Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia

Pharmacopsychiatry

Volumn 39, Issue SUPPL. 1, 2006, Pages

  Gründer, Gerhard ^a   Kungel, M ^b   Ebrecht, M ^b   Gorocs T ^b   Modell, S ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PARTIAL AGONIST; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HEADACHE; HUMAN; INSOMNIA; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE AGONISTS; HUMANS; LIMBIC SYSTEM; MESENCEPHALON; NEURAL PATHWAYS; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33644828946     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-931485     Document Type: Article

References (22)

1. Auby P, Saha AR, Ali MW, Ingenito GG, Wilber R, Bramer SL. Safety and Tolerability of Aripiprazole at Doses Higher than 30mg. Poster presented at 15th European College of Neuropsychopharmacology Congress (ECNP). Barcelona, Spain: October 2002
2. Bandelow B. Aripiprazole, a "Dopamine-Serotonin System Stabilizer" in the Treatment of Psychosis. German Journal of Psychiatry 2003; 6: 9-16
3. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978; 135: 165-173
4. Cornblatt B, Kern RS, Carson WH, Dunbar GC, Ali MW, Ingenito GG, Green MF. An Open-Label Comparison Of The Neurocognitive Effects Of Aripiprazole Vs. Olanzapine In Patients With Stable Psychosis. Poster presented at Mount Sinai Conference on Cognition & Schizophrenia. Whistler, British Columbia, Canada: April 2001
5. de Quervain DJ, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C, Nitsch RM, Papassotiropoulos A. A functional genetic variation of the 5-HT2a receptor affects human memory. Nat Neurosci 2003; 6: 1141-1142
6. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71-76
7. Gründer G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-977
8. Gründer G, Medori R, Kungel M, McQuade RD, Kikuchi T. Aripiprazol: Pharmakologie eines neuen atypischen Antipsychotikums. Der Nervenarzt 2002; 73(Suppl 1): S191
9. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A 1998; 95: 15049-15054
10. Hippius H, Medori R, Kungel M, Saha AR, McQuade RD. Safety and Tolerability of Aripiprazole. Eur Arch Psychiatry Clin Neurosci 2002; 252(Suppl l): S51
11. HoyerD, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-554
12. Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. 1. Characterization and autoradiographic localization of 5-HT1 A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res 1986; 376: 85-96
13. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771
14. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali MW, Archibald DG, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325-337
15. Marder SR, McQuade RD, Stock EG, Kaplita SB, Marcus R, Safferman AZ, Saha A, Ali MW, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-136
16. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazole: A Dopamine-Serotonin System Stabilizer. Int J Neuropsychopharmacol 2002; 5(Suppl 1): 176
17. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1159-1172
18. Müller WE. Partieller D2-Agonismus und dopaminerge Stabilisierung durch Aripiprazol. Psychopharmakotherapie 2002; 9: 120-126
19. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-1056
20. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali MW, Stock EG, String-fellow J, Ingenito G, Marder SR. Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder. Arch Gen Psychiatry 2003; 60: 681-690
21. Rüther E. Schizophrenietherapie im Wandel der Zeit, psycho 2002; 28: 539-543
22. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannais RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27: 248-259